ReviewReviews in endocrine & metabolic disorders2015
Polycystic ovary syndrome (PCOS) and endocrine disrupting chemicals (EDCs).
Review in Reviews in endocrine & metabolic disorders, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 70 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
70 citing papers in PubMed, 1 synthesis or guideline pooled it, 158 citations in OpenAlex.
- Environmental exposure to selected non-persistent endocrine disrupting chemicals and polycystic ovary syndrome: a systematic review.International journal of occupational medicine and environmental health · 2025Pooled it
- Epigenetic regulation of ovarian steroidogenesis in PCOS: HDAC inhibitors and short-chain fatty acids.Molecular biology reports · 2026Review
- The Role of Antioxidants in the Management of Polycystic Ovary Syndrome.Antioxidants (Basel, Switzerland) · 2026Review
- Interconnection between polycystic ovary syndrome, immune disorders, and reproductive outcomes.Reproduction & fertility · 2026Review
- Bisphenol a and polycystic ovary syndrome in reproductive-age women: mechanistic exploration via network toxicology and molecular docking.Journal of ovarian research · 2026Article
- Association of emerging alternatives to per- and polyfluoroalkyl substances with polycystic ovary syndrome among Chinese women: a case-control study.Scientific reports · 2026Article
- Review
- Microplastic exposure and human health risks across the life cycle: a focus on reproduction, development, and aging.Frontiers in cell and developmental biology · 2026Review
- Unveiling the potential targets and mechanisms of DEHP/BPA exposure on PCOS: insights from network toxicology and molecular docking.Journal of ovarian research · 2025Article
- Review
- Preconception, gestation, and childhood exposure to air pollution and risk of polycystic ovary syndrome (PCOS) in a US girls cohort study.Environment international · 2025Article
- Research mechanism of DBP and DEHP in the development of PCOS based on network toxicology and molecular docking.Naunyn-Schmiedeberg's archives of pharmacology · 2025Article
- Article
- Integrated chemical exposome-metabolome profiling of follicular fluid and associations with fertility outcomes during assisted reproduction.Environment international · 2025Article
- IL2RG knockout mitigates polycystic ovary syndrome pathogenesis by transitioning pyroptosis to apoptosis through the GSDME pathway.Journal of ovarian research · 2025Article
- The global burden of polycystic ovary syndrome, endometriosis, uterine fibroids, cervical cancer, uterine cancer, and ovarian cancer from 1990 to 2021.BMC public health · 2025Article
- Changing trends in the global burden of polycystic ovarian syndrome-related infertility over the past 30 years: retrospective data analysis of the global burden of disease study 2019.BMC women's health · 2025Article
- Article
- The evolution of the global disease burden of polycystic ovary syndrome and the role of regional heterogeneity in high body mass index exposure: a spatiotemporal analysis based on the global burden of disease 2021.Frontiers in reproductive health · 2025Article
- Evolving global trends in PCOS burden: a three-decade analysis (1990-2021) with projections to 2036 among adolescents and young adults.Frontiers in endocrinology · 2025Article
10 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Polycystic ovary syndrome (PCOS) is a heterogeneous disorder of unclear etiopathogenesis that is likely to involve genetic and environmental components synergistically contributing to its phenotypic expression. Endocrine disrupting chemicals (EDCs) and in particular Bisphenol A (BPA) represent a group of widespread pollutants intensively investigated as possible environmental contributors to PCOS pathogenesis. Substantial evidence from in vitro and animal studies incriminates endocrine disruptors in the induction of reproductive and metabolic aberrations resembling PCOS characteristics. In humans, elevated BPA concentrations are observed in adolescents and adult PCOS women compared to reproductively healthy ones and are positively correlated with hyperandrogenemia, implying a potential role of the chemical in PCOS pathophysiology, although a causal interference cannot yet be established. It is plausible that developmental exposure to specific EDCs could permanently alter neuroendocrine, reproductive and metabolic regulation favoring PCOS development in genetically predisposed individuals or it could accelerate and/or exacerbate the natural course of the syndrome throughout life cycle exposure.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.